Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XAZNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.5.1.16NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.165NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.444NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.160.27NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.177.68NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
AY.79 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.33NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.1.424NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
AY.29.2 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BC.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.3.13NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.56NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.10NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
GJ.1.2.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
DV.7.1.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
FL.20.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
JN.1.30NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
JR.1.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
XDENNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
JN.1.1.9NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
GK.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
HN.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
JY.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
P.7NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
XBB.1.5.42NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
GW.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
HY.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.1.371NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
AY.121.1 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
GM.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2 (Omicron)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.160.26NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.177.26NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.86.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
AY.4.10 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4245.4US
XBB.2.3.10ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
AY.121.1 (Delta)ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BN.1.3.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.2.36ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.1.5.60ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.1.5.90ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
EG.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBF.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.2.56ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
B.1.274ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.2.3.18ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.2.3.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BM.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used